{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:21:52Z","timestamp":1700612512335},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1690","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).<\/jats:p>","DOI":"10.58347\/tml.2023.1690c","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:37:21Z","timestamp":1700581041000},"page":"189-190","source":"Crossref","is-referenced-by-count":0,"title":["Sulbactam\/Durlobactam (Xacduro) for Acinetobacter Pneumonia"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,11,27]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:37:21Z","timestamp":1700581041000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1690c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":0,"journal-issue":{"issue":"1690","published-online":{"date-parts":[[2023,11,27]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1690c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]}}}